Electrophysiological interventions for treatment of congestive heart failure in pediatrics and congenital heart disease

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 1, 2007, Pages 111-118

  Dubin, Anne M ^a   Berul, Charles I ^b  

^a STANFORD UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Congenital heart defect; Heart failure; Resynchronization; Sudden death

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; ENCAINIDE; FLECAINIDE; PLACEBO; PROPAFENONE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL;

ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; CHILD CARE; CLINICAL TRIAL; COMORBIDITY; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; DEFIBRILLATION; FONTAN PROCEDURE; HEART ATRIUM ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART HEMODYNAMICS; HEART PROARRHYTHMIA; HEART RHYTHM; HEART SURGERY; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; INOTROPISM; LIVER DISEASE; LUNG DISEASE; MORBIDITY; MORTALITY; PATIENT SAFETY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THYROID DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; CHILD; DEFIBRILLATORS, IMPLANTABLE; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART DEFECTS, CONGENITAL; HEART FAILURE, CONGESTIVE; HUMANS; PACEMAKER, ARTIFICIAL; POTASSIUM CHANNEL BLOCKERS;

EID: 33846535263     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.1.111     Document Type: Review

References (82)

1. Lipshultz SE, Sleeper LA, Towbin JA et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med 348(17), 1647-1655 (2003).
2. Boucek MM, Edwards LB, Keck BM et al. The Registry of the International Society for Heart and Lung Transplantation: Sixth Official Pediatric Report - 2003. J. Heart Lung Transplant. 22(6), 636-652 (2003).
3. Rosenthal DN, Dubin AM, Chin C, Falco D, Gamberg P, Bernstein D. Outcome while awaiting heart transplantation in children: A comparison of congenital heart disease and cardiomyopathy. J. Heart Lung Transplant. 19(8), 751-755 (2000).
4. Morrow WR, Frazier E, Naftel DC. Survival after listing for cardiac transplantation in children. Prog. Pediatr. Cardiol 11(2), 99-105 (2000).
5. Steinberger J, Haines HC, Shumway SJ, Bolman RM, 3rd, Rocchini AP, Braunlin EA. Outcome after referral for pediatric transplantation. J. Heart Lung Transplant. 12(5), 760-769 (1993).
6. Nield LE, McCrindle BW, Bohn DJ, et al. Outcomes for children with cardiomyopathy awaiting transplantation. Cardiol. Young. 10(4), 358-366 (2000).
7. Dubin AM, Van Hare GF, Collins KK, Bernstein D, Rosenthal DN. Survey of current practices in use of amiodarone and implantable cardioverter defibrillators in pediatric patients with end-stage heart failure. Am. J. Cardiol. 88(7), 809-810 (2001).
8. Dubin AM, Janousek J, Rhee E et al. Resynchronization therapy in pediatric and congenital heart disease patients: An international multicenter study. J. Am. Coll. Cardiol. 46(12), 22-77-2283 (2005).
9. Janousek J, Paul T, Reimer A. Kallfelz HC. Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am. J. Cardiol 72(3), 294-300 (1993).
10. Perry JC, Garson A Jr. Flecainide acetate for treatment of tachyarrhythmias in children: Review of world literature on efficacy, safety, and dosing. Am. Heart J. 124(6), 1614-1621 (1992).
11. Perry JC, Knilans TK, Marlow D, Denfield SW, Fenrich AL, Friedman RA. Intravenous amiodarone for life-threatening tachyarrhythmias in children and young adults. J. Am. Coll. Cardiol. 22(1), 95-98 (1993).
12. Vrobel TR, Miller PE, Mostaw ND, Rakita L. A general overview of amiodarone toxicity: Its prevention, detection, and management. Prog. Cardiovasc. Dis. 31(6), 393-426 (1989).
13. Kirsh JA. Gross GJ, O'Connor S, Hamilton RM. Transcatheter cryoablation of tachyarrhythmias in children: Initial experience from an international registry. J. Am. Coll. Cardiol. 45(1), 133-136 (2005).
14. Kugler JD, Danford DA, Deal BJ et al. Radiofrequency catheter ablation for tachyarrhytmias in children and adolescents. The Pediatric Electrophysiology Society. N. Engl. J. Med. 330(21), 1481-1487 (1994).
15. Weipert J, Noebauer C, Schreiber C, et al. Occurrence and management of atrial arrhythmia after long-term Fontan circulation. J. Thorac. Cardiovasc. Surg. 127(2), 457-464 (2004).
16. Triedman JK, Saul JP, Weindling SN, Walsh EP. Radiofrequency ablation of intraatrial reentrant tachycardia after surgical palliation of congenital heart disease. Circulation 91(3), 707-714 (1995).
17. DiCarlo LA, Jr., Morady F, Krol RB, et al. The hemodynamic effects of ventricular pacing with and without atrioventricular synchrony in patients with normal and diminished left ventricular function. Am. Heart J. 114(4 Pt 1), 744-752 (1987).
18. Stephenson EA, Casavant D, Tuzi J et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am. J. Cardiol 92(7), 871-876 (2003).
19. Mavroudis C, Backer CL, Deal BJ, Johnsrude C, Strasburger J. Total cavopulmonary conversion and maze procedure for patients with failure of the Fontan operation. J. Thorac. Cardiovasc. Surg. 122(5), 863-871 (2001).
20. Collins KK, Rhee EK, Delucca JM et al. Modification to the Fontan procedure for the prophylaxis of intra-atrial reentrant tachycardia: short-term results of a prospective randomized blinded trial. J. Thorac. Cardiovasc. Surg. 127(3), 721-729 (2004).
21. Weinstein S, Cua C, Chan D, Davis JT. Outcome of symptomatic patients undergoing extracardiac Fontan conversion and cryoablation. J. Thorac. Cardiovasc. Surg. 126(2), 529-536 (2003).
22. Sheikh AM, Tang AT, Roman K et al, The failing Fontan circulation: successful conversion of atriopulmonary connections. J. Thorac. Cardiovasc. Surg. 128(1), 60-66 (2004).
23. Lewis AB, Chabot M. Outcome of infants and children with dilated cardiomyopathy. Am. J. Cardiol, 68(4), 365-369 (1991).
24. Griffin ML, Hernandez A, Martin TC et al, Dilated cardiomyopathy in infants and children. J. Am. Coll. Cardiol. 11(1), 139-144 (1988).
25. Friedman RA, Moak JP, Garson A. Jr. Clinical course of idiopathic dilated cardiomyopathy in children. J. Am. Coll. Cardiol. 18(1), 152-156 (1991).
26. Muller G, Ulmer HE, Hagel KJ, Wolf D. Cardiac dysrhythmias in children with idiopathic dilated or hypertrophic cardiomyopathy. Pediatr. Cardiol 16(2), 56-60 (1995).
27. Hayes CJ, Gersony WM. Arrhythmias after the Mustard operation for transposition of the great arteries: A long-term study. J. Am. Coll. Cardiol, 7(1), 133-137 (1986).
28. Garson A. Jr., Randall DC, Gillette PC et al. Prevention of sudden death after repair of tetralogy of Fallot: Treatment of ventricular arrhythmias. J. Am. Coll. Cardiol, 6(1), 221-227 (1985).
29. Gillette PC, Yeoman MA, Mullins CE, McNamara DG. Sudden death after repair of tetralogy of Fallot. Electrocardiographic and electrophysiologic abnormalities. Circulation 56(4 Pt 1), 566-571 (1977).
30. Sullivan ID, Presbitero P, Gooch VM, Aruta E, Deanfield JE. Is ventricular arrhythmia in repaired tetralogy of Fallot an effect of operation or a consequence of the course of the disease? A prospective study. Br. Heart J. 58(1), 40-44 (1987).
31. Deanfield JE, Ho SY, Anderson RH, McKenna WJ, Allwork SP Hallidie-Smith KA. Late sudden death after repair of tetralogy of Fallot: A clinicopathologic study. Circulation 67(3), 626-631 (1983).
32. Wiles HB, Gillette PC, Harley RA, Upshur JK. Cardiomyopathy and myocarditis in children with ventricular ectopic rhythm. J. Am. Coll. Cardiol, 20(2), 359-362 (1992).
33. Dyckner T, Wester PO. Potassium/magnesium depletion in patients with cardiovascular disease. Am. J. Med. 82(3A), 11-17 (1987).
34. Hjalmarson A. Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283(10), 1295-1302(2000).
35. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344(22), 1651-8 (2001).
36. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J. Heart Lung Transplant 23(7), 832-838 (2004).
37. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J. Am. Coll. Cardiol. 40(11), 2034-2038 (2002).
38. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: An initial multicenter experience. J. Pediatr. 138(4), 505-511 (2001).
39. Shaddy RE, Curtin EL, Sower B, et al. The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: Rationale and design. Am. Heart Failure: 144(3), 383-389 (2002).
40. Shaddy RE, Hsu DT, Boucek R et al. Multicenter Randomized Placebo-Controlled Double-Blind Trial of Carvedilol in Children with Heart Failure. In: 2006 Annual Scientific Sessions of the American College of Caridology, Atlanta, GA, USA (2006).
41. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med 324(12), 781-788 (1991).
42. Fish FA, Gillette PC, Benson DW, Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. J. Am. Coll. Cardiol. 18(2), 356-365 (1991).
43. Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am. J. Cardiol. 74(6), 573-577 (1994).
44. Coumel P, Fidelle J. Amiodarone in the treatment of cardiac arrhythmias in children: One hundred thirty-five cases. Am. Heart J. 100(6 Pt 2), 1063-1069 (1980).
45. Saul JP, Scott WA. Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: A randomized, double-blind, antiarrhythmic drug trial. Circulation 112(22), 3470-3477 (2005).
46. Saul JP, Ross B, Schaffer MS, et al. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Clin. Pharmacol, Ther. 69(3), 145-157 (2001).
47. Tanel RE, Walsh EP, Lulu JA, Saul JP. Sotalol for refractory arrhythmias in pediatric and young adult patients: Initial efficacy and long-term outcome. Am. Heart J. 130(4), 791-797 (1995).
48. Morwood JG, Triedman JK, Berul CI, et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm 1(3), 301-308 (2004).
49. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 341(25), 1882-1890 (1999).
50. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346(12), 877-883 (2002).
51. Lorga-Filho A, Geelen P, Vanderheyden M, et al. Early benefit of implantable cardioverter defibrillator therapy in patients waiting for cardiac transplantation. Pacing Clin. Electrophysiol. 21(9), 1747-50 (1998).
52. Forni A, Faggian G, Luciani GB, Lamascese N, Chiominto B, Mazzucco A. Safety and efficacy of automatic implantable defibrillator used as a bridge to heart transplant. Transplant Proc. 33(4), 2489-2492 (2001).
53. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl, J. Med. 352(3), 225-237 (2005).
54. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl, J. Med 335(26), 1933-1940 (1996).
55. Kadish A. Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med 350(21), 2151-2158 (2004).
56. Aranda JM, Jr., Woo GW, Schofield RS et al. Management of heart failure after cardiac resynchronization therapy: Integrating advanced heart failure treatment with optimal device function. J. Am. Coll. Cardiol. 46(12), 2193-2198 (2005).
57. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med 352(15), 1539-1549 (2005).
58. Leon AR, Abraham WT, Curtis AB et al. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: Combined results of over 2,000 patients from a multicenter study program. J. Am. Coll. Cardiol 46(1.2), 2348-2356 (2005).
59. Carson P, Anand I, O'Connor C et al. Mode of death in advanced heart failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J. Am. Coll. Cardiol. 46(12), 2329-2334 (2005).
60. Dubin AM, Berul CI, Bevilacqua LM et al. The use of implantable cardioverter-defibrillators in pediatric patients awaiting heart transplantation. J. Card Fail. 9(5), 375-379 (2003).
61. Link MS, Hill SL, Cliff DL et al. Comparison of frequency of complications of implantable cardioverter-defibrillators in children versus adults. Am. J. Cardiol. 83(2), 263-266, A5-6 (1999).
62. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J. Cardiovasc. Electrophysiol 15(1), 72-76 (2004).
63. Berul CI, Triedman JK, Forbess J et al. Minimally invasive cardioverter defibrillator implantation for children: An animal model and pediatric case report. Pacing Clin. Electrophysiol. 24(12), 1789-1794 (2001).
64. Stephenson EA. Batta AS, Knilans TK et al. A multicenter experience with novel implantable cardioverter defibrillator configurations in pediatric and congenital heart disease populations. J. Cardiovasc. Electrophysiol 17, 41-46 (2006).
65. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350(21), 2140-2150 (2004).
66. Cazeau S, Ritter P, Lazarus A, et al. Multisite pacing for end-stage heart failure: Early experience. Pacing Clin. Electrophysiol. 190(11 Pt 2), 1748-1757 (1996).
67. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventicular conduction delay. N. Engl. J. Med. 344(12), 873-880 (2001).
68. Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure. results of an acute hemodynamic study. Circulation 96(10), 3273-3277 (1997).
69. Kass DA, Chen CH, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 99(12), 1567-1573 (1999).
70. Nelson GS, Berger RD, Fetics BJ et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 102(25), 3053-3059 (2000).
71. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 289(20), 2685-2694 (2003).
72. Alexander ME, Berul CI, Fortescue EB et al. Who is eligible for cardiac resyncrhonizationtherapy in pediatric cardiology? Heart Rhythm 1 (1S), S122 (2004).
73. Zimmerman FJ, Starr JP, Koenig PR, Smith P, Hijazi ZM, Bacha EA. Acute hemodynamic benefit of multisite ventricular pacing after congenital heart surgery. Ann. Thorac. Surg. 75(6), 1775-1780 (2003).
74. Janousek J, Vojtovic P, Hucin B et al. Resynchronization pacing is a useful adjunct to the management of acute heart Failure after surgery for congenital heart defects. Am. J. Cardiol 88(2), 145-152 (2001).
75. Dubin AM, Feinstein JA. Reddy VM, Hanley FL, Van Hare GF, Rosenthal DN. Electrical resynchronization: A novel therapy for the failing right ventricle. Circulation 107(18), 2287-2289 (2003).
76. Bacha EA, Zimmerman FJ, Mor-Avi V et al. Ventricular resynchronization by multisite pacing improves myocardial performance in the postoperative single-ventricle patient. Ann. Thorac. Surg. 78 (5), 1678-1683 (2004).
77. Stephenson EA, Cecchin F, Alexander ME, Triedman JK, Walsh EP, Bend CI. Relation of right ventricular pacing in tetralogy of Fallot to electrical resynchronization. Am. J. Cardiol 93(11), 1449-1152, A12 (2004).
78. Sun JP, Chinchoy E, Donal E, et al. Evaluation of ventricular synchrony using novel Doppler echocardiographic indices in patients with heart Failure receiving cardiac resynchronization therapy. J. Am. Soc. Echocardiogr. 17(8), 845-850 (2004).
79. Pham PP, Balaji S, Shen I, Ungerleider R, Li X, Sahn DJ. Impact of conventional versus biventricular pacing on hemodynamics and tissue Doppler imaging indexes of resynchronization postoperatively in children with congenital heart disease. J. Am. Coll. Cardiol. 46(12), 2284-2289 (2005).
80. Rhee EK. Cardiac resynchronization therapy in pediatrics: Emerging technologies for emerging indications. Curr Treat. Options Cardiovasc. Med.7(5), 399-409 (2005).
81. Khairy P, Fournier A, Thibault B, Dubuc M, Therien J, Vobecky SJ. Cardiac resynchronization therapy in congenital heart disease. Int. J. Cardiol. 109(2), 160-168 (2006).
82. Janousek J, Tomek V, Chaloupecky VA, et al. Cardiac resynchronization therapy: A novel adjunct to the treatment and prevention of systemic right ventricular failure. J. Am. Coll. Cardiol. 44(9), 1927-1931 (2004).